Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis (acellular), measles, mumps, rubella, and varicella vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This combination refers to the co-administration of three distinct vaccine types: the DTaP vaccine (diphtheria, tetanus, and acellular pertussis), the MMR vaccine (measles, mumps, and rubella), and the varicella (chickenpox) vaccine. While not currently available as a single heptavalent injection, these vaccines are routinely co-administered during pediatric immunization schedules, typically at 12-15 months and 4-6 years of age. The DTaP component provides active immunity against bacterial toxins and pathogens through toxoids and purified proteins, while the MMR and varicella components are live-attenuated viral vaccines. Clinical data support the safety and immunologic non-interference of giving these vaccines during the same clinical visit, often using a combination MMRV product alongside a DTaP-based injection.
- Brand names
- ProQuadM-M-R IIVARIVAXKinrixQuadracel
- Other names
- varicella vaccine + DTaP + MMRDTaP-MMR-VaricellaDTaP + MMRVMMR-V + DTaP
02
Targets
Fim2 (Bordetella pertussis fimbrial protein 2)HCV E1 (Hepatitis C virus envelope glycoprotein E1)Varicella-zoster virus envelope glycoproteins gB, gH/gL, and gIHMPV F (Human metapneumovirus fusion protein)gE (VZV glycoprotein E)Diphtheria toxinMV-H (Measles virus hemagglutinin protein)
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis (acellular), measles, mumps, rubella, and varicella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis (acellular), measles, mumps, rubella, and varicella vaccine.